咪唑并[1,2-a]吡啶-2-胺 | 39588-26-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 咪唑并[1,2-a]吡啶-2-胺
• 中文别名: 咪唑并[1,2-a]吡啶-2-胺盐酸盐；咪唑并〔1,2-A]吡啶-2-胺
• 英文名称: 2-aminoimidazo[1,2-a]pyridine
• 英文别名: Imidazo[1,2-A]pyridin-2-amine
• CAS: 39588-26-6
• 化学式: C₇H₇N₃
• mdl: MFCD09836159
• 分子量: 133.153
• InChiKey: CQABHABFPKXGAF-UHFFFAOYSA-N

物化性质

• 熔点：
  73-83 °C
• 密度：
  1.32±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  咪唑并[1,2-a]吡啶-2-胺 在 盐酸 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 、 氯仿 、 水 为溶剂， 反应 11.0h， 生成
  参考文献：
  名称：

  Pyrido-imidazodiazepinones as a new class of reversible inhibitors of human kallikrein 7

  摘要：

  The human tissue kallikrein-7 (KLK7) is a chymotryptic serine protease member of tissue kallikrein family. KLK7 is involved in skin homeostasis and inflammation. Excess of KLK7 activity is also associated with tumor metastasis processes, especially in ovarian carcinomas, prostatic and pancreatic cancers. Development of Kallikrein 7 inhibitors is thus of great interest in oncology but also for treating skin diseases. Most of the developed synthetic inhibitors present several drawbacks such as poor selectivity and unsuitable physico-chemical properties for in vivo use. Recently, we described a practical sequence for the synthesis of imidazopyridine-fused [1,3]-diazepines. Here, we report the identification of pyrido-imidazodiazepinone core as a new potential scaffold to develop selective and competitive inhibitors of kallikrein-related peptidase 7. Structure-activity relationships (SAR), inhibition mechanisms and selectivity as well as cytotoxicity against selected cancer cell lines were investigated. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.02.008
• 作为产物：
  描述：

  磺胺吡啶 在 sodium hydroxide 、 水 作用下， 生成 咪唑并[1,2-a]吡啶-2-胺
  参考文献：
  名称：

  Bristow et al., Journal of the Chemical Society, 1954, p. 616,62O

  摘要：

  DOI：

文献信息

• Selective C-Acylation of 2-Aminoimidazo[1,2-<i>a</i>]pyridine: Application to the Synthesis of Imidazopyridine-Fused [1,3]Diazepinones
  作者：Nicolas Masurier、Roberta Aruta、Vincent Gaumet、Séverine Denoyelle、Emmanuel Moreau、Vincent Lisowski、Jean Martinez、Ludovic T. Maillard

  DOI：10.1021/jo300364d

  日期：2012.4.6

  2]imidazo[4,5-d][1,3]diazepin-5-ones which form a new family of azaheterocycle-fused [1,3]diazepines were synthesized in four steps with 17–66% overall yields. The key step consists of a selective C-acylation reaction of easily accessible 2-aminoimidazo[1,2-a]pyridine at C-3.

  一系列20个光学纯的3,4-二氢-5 H-吡啶并[1'，2'：1,2]咪唑并[4,5- d ] [1,3]二氮杂-5-酮形成一个新家族分四步合成了氮杂杂环融合的[1,3]二氮杂ze，总产率为17-66％。关键步骤包括在C-3处容易获得的2-氨基咪唑并[1,2- a ]吡啶的选择性C-酰化反应。
• MACROLIDE DERIVATIVES
  申请人：Kashimura Masato

  公开号：US20090076253A1

  公开（公告）日：2009-03-19

  Compounds represented by formula (I) and the formula (IV) have an inhibitory activity of MMP-9 production, therefore, are useful as a medicine agent with fewer side effects than conventional MMP enzyme activity inhibitors, as a prophylactic and therapeutic drug for oncogenic angiogenesis, chronic rheumatoid arthritis, vascular intimal thickening after a percutaneous coronary transluminal angioplasty, vascular atherosclerosis, hemorrhagic apoplexy, acute myocardial infarction, chronic heart failure, aneurysm, lung cancer metastasis, adult respiratory distress syndrome, asthma, interstitial pulmonary fibrosis, chronic rhinosinusitis, bronchitis or chronic obstructive pulmonary disease (COPD).

  由公式（I）和公式（IV）表示的化合物具有抑制MMP-9产生的活性，因此，它们可用作药物代理，其副作用比传统的MMP酶活性抑制剂少，作为预防和治疗肿瘤血管生成、慢性类风湿关节炎、经皮冠状动脉病变介入治疗后的血管内膜增厚、血管动脉粥样硬化、出血性中风、急性心肌梗死、慢性心力衰竭、动脉瘤、肺癌转移、成人呼吸窘迫综合征、哮喘、间质性肺纤维化、慢性鼻窦炎、支气管炎或慢性阻塞性肺疾病（COPD）的药物。
• Heterocyclization of Functionalized Vinylic Derivatives of Imidazo[1,2-<i>a</i>]pyridines
  作者：Jean M. Chezal、Emmanuel Moreau、Gregory Delmas、Alain Gueiffier、Yves Blache、Gérard Grassy、Claire Lartigue、Olivier Chavignon、Jean C. Teulade

  DOI：10.1021/jo015582x

  日期：2001.10.1

  functionalized vinylic derivatives of imidazo[1,2-a]pyridines was explored experimentally and theoretically using semiempirical AM1 and ab initio methods. A range of functionalized vinylic derivatives (azido, amino, and carbodiimide groups) were prepared for conversion into pyrroloazaindoles 19-22, imidazo[1,x]-, (x = 5, 6, 7, 8), [2,6]-, and [2,7]naphthyridines 28-30, 35-38 by thermal reaction. In the case

  咪唑并[1,2-a]吡啶的官能化乙烯基衍生物的杂环化使用半经验AM1和从头算的方法在理论上进行了探索。制备了一系列官能化的乙烯基衍生物（叠氮基，氨基和碳二亚胺基团），用于转化为吡咯并氮杂吲哚19-22，咪唑并[1，x]-，（x = 5、6、7、8），[2,6] -和[2,7]萘啶28-30、35-38通过热反应。在乙烯基位于5位的情况下，还观察到围成环。对实验和理论数据进行了比较和讨论。
• Methods of treating cytokine mediated diseases
  申请人：Boehringer Ingelheim Pharmaceuticals, Inc.

  公开号：US20030130309A1

  公开（公告）日：2003-07-10

  Disclosed are methods of treating certain cytokine mediated diseases or conditions using novel aromatic heterocyclic compounds of the formula(I) wherein Ar 1 ,Ar 2 ,L,Q and X are described herein. 1

  披露了使用公式(I)中描述的新芳香杂环化合物治疗特定细胞因子介导的疾病或症状的方法，其中Ar1，Ar2，L，Q和X如下所述。
• APOPTOSIS-INDUCED AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
  申请人：AbbVie Inc.

  公开号：US20130096120A1

  公开（公告）日：2013-04-18

  Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.

  揭示了抑制抗凋亡Bcl-xL蛋白活性的化合物，含有这些化合物的组合物以及治疗在其中表达抗凋亡Bcl-xL蛋白的疾病的方法。